Evidence strength for the context described on this page.
PEPTIDE ATLAS / SEXUAL & REPRODUCTIVE / BREMELANOTIDE
EvidenceHigh for approved indicationi
RegulatoryFDA-approvedi
Bremelanotide

An as-needed melanocortin therapy for acquired, generalized HSDD in selected premenopausal women.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Bremelanotide is.
A melanocortin receptor agonist approved for acquired, generalized hypoactive sexual desire disorder in selected premenopausal women. The diagnosis excludes symptoms caused by other medical or psychiatric conditions, relationship problems, or medication/substance effects. It is not approved for men, postmenopausal women or performance enhancement.
Activates melanocortin receptors, including in the central nervous system. How it improves HSDD is not established; receptor activity is not a complete explanation of clinical benefit.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Modest improvement in desire and related distress for the labeled population
- Sexual-performance enhancement
- Treatment of erectile dysfunction in men
- General libido enhancement without HSDD assessment
- Safety of compounded PT-141 products
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Blood pressure and cardiovascular eligibility
- Nausea and treatment tolerability
- Meaningful change in desire-related distress
- Persistent skin or gum darkening
SAFETY
Risks, red flags and reasons to avoid it.
- Transient blood-pressure increase and heart-rate reduction
- Nausea, flushing, headache and injection reactions
- Focal hyperpigmentation that may not fully resolve
- Reduced absorption of some oral medicines due to slowed gastric emptying
- Uncontrolled hypertension
- Known cardiovascular disease
- More than label frequency
- Using it for sexual performance rather than diagnosed HSDD
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved autoinjector; compounded bremelanotide is not the approved product.
The label is far narrower than 'libido peptide.' Diagnosis, sex, menopausal status, cardiovascular risk and dosing frequency all matter.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to sexual & reproductive peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools